Mocetinostat (MGCD0103)

Name: Mocetinostat (MGCD0103)
Brand: Selleck Chemicals
SKU: S1122
Rating: 5 (85 reviews)

For research use only.

Catalog No.S1122 Synonyms: MG0103

85 publications

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Selleck's Mocetinostat (MGCD0103) has been cited by 85 publications

Cancer Cell, 2021, S1535-6108(20)30662-0

PubMed: 33482121 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4337

PubMed: 32152395 ( click the link to review the publication )

Front Genet, 2020, 11:80

PubMed: 32158467 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:4705615

PubMed: 32775424 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

J Cancer, 2020, 11(7):1915-1926

PubMed: 32194803 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:752

PubMed: 32850856 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Oncol, 2019, 13(9):1944-1958

PubMed: 31225930 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )
JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

J Mol Cell Cardiol, 2017, 112:74-82

PubMed: 28886967 ( click the link to review the publication )

Biotechnol Bioeng, 2017, 114(11):2660-2667

PubMed: 28667749 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

Pain Physician, 2017, 20(5):E673-E685

PubMed: 28727712 ( click the link to review the publication )

Theriogenology, 2017, 87:298-305

PubMed: 27742403 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Circ J, 2017, 82(1):192-202

PubMed: 28747611 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16036

PubMed: 27551526 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Lipid Res, 2016, 57(5):868-81

PubMed: 27013100 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Future Med Chem, 2016, 8(13):1553-71

PubMed: 26971619 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1015-24

PubMed: 27185186 ( click the link to review the publication )

Hypertens Res, 2016, 39(10):709-716

PubMed: 27278287 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Nucleic Acids Res, 2015, 10.1093/nar/gkv188

PubMed: 25769527 ( click the link to review the publication )
Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Oncotarget, 2015, 6(24):20449-65

PubMed: 26036259 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Blood, 2014, 123(10):1535-43

PubMed: 24449212 ( click the link to review the publication )

J Heart Lung Transplant, 2014, 33(6):644-53

PubMed: 24746638 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

J Neurosci, 2014, 34(17):6112-22

PubMed: 24760871 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

BMC Biol, 2014, 10.1186/1741-7007-12-30

PubMed: 24779377 ( click the link to review the publication )

Oncogenesis, 2014, 3:e127

PubMed: 25402609 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-17

PubMed: 24200994 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2912-20

PubMed: 25220405 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Fibrogenesis Tissue Repair, 2014, 7:10

PubMed: 25024745 ( click the link to review the publication )

Mol Cell, 2013, 52(3):406-20

PubMed: 24120667 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Oncogene, 2013, 33(5):653-64

PubMed: 23524580 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )
Pain, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

J Dent Res, 2013, 93(2):148-54

PubMed: 24334408 ( click the link to review the publication )

Mol Pharm, 2013, 10(1):307-18

PubMed: 23186311 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(5):e000317

PubMed: 24088507 ( click the link to review the publication )

Melanoma Res, 2013, 23(5):341-8

PubMed: 23963286 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Oncogene, 2012, 32(33):3896-903

PubMed: 22945647 ( click the link to review the publication )

Biochem J, 2012, 447(3):457-64

PubMed: 22908849 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52095

PubMed: 23251689 ( click the link to review the publication )

Oncogene, 2011, 30(27):3062-72

PubMed: 21577204 ( click the link to review the publication )

J Biol Chem, 2011, 286(27):23842-51

PubMed: 21489983 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC11 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)
0.15 μM	0.29 μM	0.59 μM	1.66 μM

In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PBMC	NHrxXJBCeG:ydH;zbZMhSXO\|YYm=	MmrZNE42NzJxMzFOwG0>	MkKwNlQwPDhiaB?=		NHjFR5ZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2ME[5OFcoRjJyNEC2PVQ4RC:jPh?=
HeLa	MlHjSpVv[3Srb36gRZN{[Xl?	NGezS2cyOCEQvF5CpC=>	NVXDUYh3PyCq	MXfEUXNQ	NF;ZVFJlcXO{dYD0d{Bvd3KvYXygd5BqdmSuZTDjbIVkc3CxaX70JIZ2dmO2aX;u	M4\PUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUO4PFQxLz5{MEWzPFg1ODxxYU6=
HeLa	MX;GeY5kfGmxbjDBd5NigQ>?	M3ftPVExKM7:TdMg	M1HBTFYwOTJxMkSgbC=>	MXvEUXNQ	NUTaXVlKcW6mdXPld{BucXSxdHnjJIFk[3WvdXzheIlwdiCjbnSg[IVt[XmnZDDwNlEh\XiycnXzd4lwdg>?	NHOwT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWzPFg1OCd-MkC1N\|g5PDB:L3G+
HeLa	NIXV[VBHfW6ldHnvckBCe3OjeR?=	MnXFNE4{NTFyIN88US=>	MoTxPEBp	M3PtVmROW09?	MWDpcoNz\WG\|ZYOgZ4F{eGG\|ZTCzJIFv\CB5IHHjeIl3[XSrb36g[I9{\SCmZYDlcoRmdnSueR?=	M1jpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUO4PFQxLz5{MEWzPFg1ODxxYU6=
HeLa	MWDGeY5kfGmxbjDBd5NigQ>?	NVLHO5hEOC5\|LUGwJO69VQ>?	NFn4eZg5KGh?	NWfXeJM{TE2VTx?=	NVnRNoZLcW6lcnXhd4V{KGGlZYT5cIF1\WRiSEOgT\|khMEh\|S{nBZ{kh[XRiMUCg{txO	NF;xO3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWzPFg1OCd-MkC1N\|g5PDB:L3G+
DMS114	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTZ2MDDuUS=>	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H82	NF;TOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHOwPVVKSzVyPUK1NEBvVQ>?	MnzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H146	M{S3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLrRpZKSzVyPUO1JI5O	NFu3cno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4NlY1Oyd-MkC2PFI3PDN:L3G+
H526	M3fuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LXTGlEPTB;NEiwJI5O	MlKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
KM-H2	Moi3SpVv[3Srb36gRZN{[Xl?	MmexNeKh\|ryP	NUmxfXZ6OC5{NT20PEBp	M2DOOGROW09?	NWPrclBK[WO2aY\heIV{KE6ILXvC	MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	NYTGdIxkTnWwY4Tpc44hSXO\|YYm=	NFPPenAyyqEQvF2=	MXOwMlI2NTR6IHi=	M13afGROW09?	NWjK[Wlx[WO2aY\heIV{KE6ILXvC	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
HD-LM2	MXfGeY5kfGmxbjDBd5NigQ>?	MoftNeKh\|ryP	M2q1fFAvOjVvNEigbC=>	NXLKRZo2TE2VTx?=	MnfwZYN1cX[jdHXzJG5HNWuE	MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
KM-H2	MVnGeY5kfGmxbjDBd5NigQ>?	NUjmR2dJOC53L{Gg{txO	MnPqNlQwPDhiaB?=	Mkj6SG1UVw>?	MWH1dJJm\3WuYYTld{BVVkZvzsGg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	MYrGeY5kfGmxbjDBd5NigQ>?	M3jMcVAvPS9zIN88US=>	M2PkeVI1NzR6IHi=	MXzEUXNQ	NEnEOWJ2eHKnZ4XsZZRmeyCWTl[t{tEh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	NUXGXppFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	NGrzfXdHfW6ldHnvckBCe3OjeR?=	NGrxb4ExNjVxMTFOwG0>	NFPkXGEzPC92ODDo	NWDINotHTE2VTx?=	MVH1dJJm\3WuYYTld{BVVkZvzsGg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	NEj0bXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
KM-H2	NF3BT5dHfW6ldHnvckBCe3OjeR?=	MVexxsDPxE1?	NFrHRW4zPC92ODDo	Mmr0SG1UVw>?	MWPkc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	NGLQTJhHfW6ldHnvckBCe3OjeR?=	M4O4WVHDqM7:TR?=	M1PJPVI1NzR6IHi=	NGrrV3BFVVOR	M2rCPYRwf26{ZXf1cIF1\XNiWFnBVEwh[WO2aY\heIVlKGOjc4Dhd4V{KDliYX7kJFM>	MlvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
HD-LM2	NFv6bmRHfW6ldHnvckBCe3OjeR?=	M3jrelHDqM7:TR?=	NHLPXpkzPC92ODDo	Mo\OSG1UVw>?	M{DTWYRwf26{ZXf1cIF1\XNiWFnBVEwh[WO2aY\heIVlKGOjc4Dhd4V{KDliYX7kJFM>	M{HT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	NW\PVnNLSXCxcITvd4l{KEG\|c3H5	MoTxNE4yNzBwNT:xJO69VQ>?	MWO0PEBp	M2n3fmROW09?	NF[1R5FqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M4DLdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
L428	MX7BdI9xfG:\|aYOgRZN{[Xl?	MUmwMlEwOC53L{Gg{txO	NUH2VWhEPDhiaB?=	M3XqUmROW09?	NEntWoFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NEDHWGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
HD-LM2	NITkUWNCeG:ydH;zbZMhSXO\|YYm=	NX;2U5pvOC5zL{CuOU8yKM7:TR?=	M4HUc\|Q5KGh?	NHz0RmJFVVOR	NYjyZ2pqcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M{LLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	M3zqVGZ2dmO2aX;uJGF{e2G7	M3TaRlAvOS1{IN88US=>	MlrXNlQhcMLi	MUnEUXNQ	MoOyd4hwf3NiYXPleJlt[XSrb36gc4YhcGm\|dH;u[UA{KGGwZDD1dJJm\3WuYYTpc44hd2ZidHjlJINmdGxiY4njcIUhemWpdXzheI9zgSCycn;0[YlvKHB{MR?=	MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	MmfMSpVv[3Srb36gRZN{[Xl?	MVqwMlEuOiEQvF2=	MUWyOEBpyqB?	MYHEUXNQ	MlO3d4hwf3NiYXPleJlt[XSrb36gc4YhcGm\|dH;u[UA{KGGwZDD1dJJm\3WuYYTpc44hd2ZidHjlJINmdGxiY4njcIUhemWpdXzheI9zgSCycn;0[YlvKHB{MR?=	M3z1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MXfGeY5kfGmxbjDBd5NigQ>?	MV[wMlEuOiEQvF2=	MUeyOEBpyqB?	M{jlcWROW09?	NVXNNVhve2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB\|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=>	NWH4VFQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
KM-H2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrtO\|LDqGh?	MnjtSG1UVw>?	NIK2cGFKSzVyPUKuPFYh\|ryP	NVHRWVFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXe3NuKhcA>?	M4[3OWROW09?	NULKeYllUUN3ME2xMlk3KM7:TR?=	MonvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
HD-LM2	NF;FZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUHXNlc6PzMEoHi=	M1ezUmROW09?	MlXjTWM2OD1zLki4JO69VQ>?	M2TTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
LP1	NWHJPWJxTnWwY4Tpc44hSXO\|YYm=	NYHJem82OcLizszN	NX[3VphuOjRiaB?=		NXHQcWox\W6qYX7j[ZMhPS2DQz3pcoR2[2WmIF3BS2UuSTNiZ3Xu[UBmgHC{ZYPzbY9v	M12xTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUexPFIyLz5{MUG3NVgzOTxxYU6=
ANBL6	MWnGeY5kfGmxbjDBd5NigQ>?	NVTSfnBtOcLizszN	NXnQ[45bOjRiaB?=		Mofl[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO\|aX;u	NFHKS5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NVgzOSd-MkGxO\|E5OjF:L3G+
HMEC	NX;OXZVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTF7IN88US=>	MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
SW620	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjETWM2OD1zIN88US=>	NXHqfYxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVc1PTVpPkKxN\|E4PDV3PD;hQi=>
SW48	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwODFOwG0>	NX\z[pB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVc1PTVpPkKxN\|E4PDV3PD;hQi=>
HT-29	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEGwRWtKSzVyPUCuO{DPxE1?	NEHjdJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
HCT15	NYLJUHZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLpU5RwUUN3ME2wMlch\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzN{S1OUc,OjF\|MUe0OVU9N2F-
PAXF 1657L†	NEnNNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjoSWM2OD1yLkOg{txO	M37iUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
PAXF 546L†	NF:xb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWmxWYJsTUN3ME2xMlUh\|ryP	NXjme3c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|U3PzlpPkKxN\|c2Pjd7PD;hQi=>
Panc-1	MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkH6SWM2OD1zLkig{txO	M1nR[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
MiaPaca-2	NXfBV4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK5Z3ZGSzVyPUCuOkDPxE1?	Mnj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
AsPC-1	NFTQ[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjFR\|UxRTNwOTFOwG0>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5NU[3PUc,OjF\|N{W2O\|k9N2F-
BxPC-3	M4riXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnKNWxGSzVyPUGuNUDPxE1?	NEjxVI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3OVY4QSd-MkGzO\|U3Pzl:L3G+
MMCs	NVjNU5p{TnWwY4Tpc44hSXO\|YYm=	MYGxxsDPxE1?	MX62MVI1KGh?		M17NOoRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdIOgeIhmKHS{aX3leIh6dGG2aX;uJIxmfmWuIH;mJGg{NUt7IDjIN{1MQW2nMzm=	NVXucGxQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVE{PzhpPkK0OFUyOzd6PD;hQi=>
MMCs	MYjGeY5kfGmxbjDBd5NigQ>?	MlflNeKh\|ryP	M4n6PFI1KGh?		NG[5fFBifWevZX70d{BodG:kYXygZYNmfHmuYYTpc44hdGW4ZXzzJI9nKGirc4TvcoUhUDNvS{mvNVQhMEh\|LVu5M\|E1[WNrIHHu[EBJPC2NMUKgLGg1NUtzMnHjLS=>	NXLHTVZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVE{PzhpPkK0OFUyOzd6PD;hQi=>
MMCs	MULGeY5kfGmxbjDBd5NigQ>?	MkThNeKh\|ryP	NWjCV3lnOjRiaB?=		NWO1dJFzcW6lcnXhd4V{KEiDVDDhZ5Rqfmm2eR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUO3PEc,OjR2NUGzO\|g9N2F-
MMCs	Mm\BSpVv[3Srb36gRZN{[Xl?	MnvRNE42NzFizszN	M4\6ZlI1KGh?		MYjzbI94eyB2NT3mc4xlKHO2aX31cIF1cW:wIHnuJINIVVBibHX2[Yx{	M2fYVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	NYLodWZMTnWwY4Tpc44hSXO\|YYm=	NWrueGFZOSEQvH2=	M{XjfVAuPDhiaB?=		MYLpcoNz\WG\|ZYOgUnBTSSCycn;0[YlvKGW6cILld5Nqd28EoEKuO-KBmzNwNTDmc4xl	M3jK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
Panc1	MlzYR4VtdCCYaXHibYxqfHliQYPzZZk>	NHzBZo8yyqEQvF2=	M{Ww[\|czyqCq	MmrjSG1UVw>?	NYe5T5RX\W6qYX7j[ZMh\2WvY3n0ZYJqdmVvaX7keYNmeyClZXzsJJZq[WKrbHn0fUBl\WO{ZXHz[S=>	NUC5eJJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|I6PDFpPkK1PFczQTRzPD;hQi=>
Panc1	NHviWXlCeG:ydH;zbZMhSXO\|YYm=	MljyNeKh\|ryP	MV:3NuKhcA>?	NVnnUVhLTE2VTx?=	M1fFeJNmdnOrdHn6[ZMhWGGwY{GgZ4VtdHNiZn;yJIdmdWOrdHHibY5mNWmwZIXj[YQh[XCxcITvd4l{	NGHMW409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
Panc1	MUXGeY5kfGmxbjDBd5NigQ>?	NFv2VoMxNjVxMT:yMlUh\|ryP	M2DacVQ5KGh?	NV[zellLTE2VTx?=	NXTYc4dQemWmdXPld{BmgHC{ZYPzbY9vKG:oIGrFRlEhd25iYn;0bEBuWk6DIHHu[EBxem:2ZXnuJIxmfmWuwrC=	NYrzRlFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|I6PDFpPkK1PFczQTRzPD;hQi=>
Panc1	MYnGeY5kfGmxbjDBd5NigQ>?	M4PvWVAvPS9zL{KuOUDPxE1?	NVjzUJlmPDhiaB?=	NFjubVZFVVOR	MkPPeZBz\We3bHH0[ZMhdWmULUKwNy=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5Mkm0NUc,OjV6N{K5OFE9N2F-
MOLP8	NVLD[o0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4XRXlQ5KGh?		NI\sdGtKSzVyPUCuOuKyKDBwMEVOwG0>	NFjyU2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5NVUyQCd-Mk[wPVE2OTh:L3G+
T47D	M2iyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDrR5QyPDhiaB?=		MmHWTWM2OD1zLkG3JO69VQ>?	MlruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|N{iwN\|goRjJ4M{e4NFM5RC:jPh?=
MCF7	M{jRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{KwSVQ5KGh?		MV\JR\|UxRTBwNkeg{txO	Mlj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|N{iwN\|goRjJ4M{e4NFM5RC:jPh?=
BT549	NF:xSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnW5OFghcA>?		MUDJR\|UxRTRwM{ig{txO	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN5OECzPEc,OjZ\|N{iwN\|g9N2F-
MDA-MB-231	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFLPO3g1QCCq		MnnxTWM2OD1\|LkC0JO69VQ>?	NUS5U2ZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO\|gxOzhpPkK2N\|c5ODN6PD;hQi=>
HEK293	M1i5c2Z2dmO2aX;uJIF{e2G7				MWHJcohq[mm2aX;uJI9nKEiGQVOxJIlvKEiHS{K5N{Bk\WyuczygTWM2OD1yLkGz{txO	NEXmeVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
HEK293	MmDpSpVv[3Srb36gZZN{[Xl?				MoXhTY5pcWKrdHnvckBw\iCKRFHDN{BqdiCKRVuyPVMh[2WubIOsJGlEPTB;MD62Ne69VQ>?	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEi1OlMoRjF6M{C4OVY{RC:jPh?=
HCT116	NU[ybpB2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4KwVlczKGi{cx?=		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwMkpOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
HCT116	Ml\SSpVv[3Srb36gZZN{[Xl?				M1;Mfmlv\HWldHnvckBw\iCyMkHjbZAwf2GoMTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gTGNVOTF4IHPlcIx{KHKnbHH0bZZmKHSxIF3TNlc2NCCHQ{WwQVAvPDYQvF2=	NVK1S3JvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
Du145	M2rnTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NH7oU2w4OiCqcoO=		NEjGV4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFT1NVQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD62O:69VQ>?	NF\JS3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3NFM3Pid-MUi1O\|A{PjZ:L3G+
A549	M1H4RWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NE[4c3I4OiCqcoO=		MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjoQvF2=	MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
HCT116	NXLFSWxpS2WubDDjfYNt\SCjc4PhfS=>				M1HnOmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTygSWM2ODxzzszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
T24	NGnQVohHfW6ldHnvckBie3OjeR?=				NGXEUHhKdmS3Y4Tpc44hd2ZiSEOgbIl{fG:wZTDhZ4V1gWyjdHnvckBqdiCqdX3hckBVOjRiY3XscJMhemWuYYTpeoUhfG9iTWOyO\|UtKEWFNUC9NU4{QM7:TR?=	NG[xenk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3NFM3Pid-MUi1O\|A{PjZ:L3G+
HCT116	MWnBdI9xfG:\|aYOgZZN{[Xl?	NIOwblgyKHWP			M3rMT2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gTGNVOTF4IHPlcIx{KGG2IEGgeW0>	MnuxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
HCT116	MmW0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NIKyR3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5\|zszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNEOwOEc,OTlzMUSzNFQ9N2F-
HCT116	NGrGTXhHfW6ldHnvckBie3OjeR?=		MofKNVYhcHK\|		NH32cVFKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44hcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJJR2[nWuaX6gcIV3\WxiYX\0[ZIhOTZiaILzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE43\|ryP	NV\3Zo1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQ{ODRpPkG5NVE1OzB2PD;hQi=>
T24	M3f5OWZ2dmO2aX;uJIF{e2G7		NUPPdWFFOTZiaILz		NGC4UolKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:wIHnuJIh2dWGwIGSyOEBk\WyuczDh[pRmeiBzNjDodpMh[nliaX3teY5w[myxdITpcoctKEWFNUC8Ne69VQ>?	NEfpR3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFMxPCd-MUmxNVQ{ODR:L3G+
HCT116	MmX0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NVvuNW1iSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFnDOVA:OC5\|Md88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ3MEKyNUc,OjF4NUCyNlE9N2F-
H1299	NWnvVm5vSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				Mk\hRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKMUK5PUBk\WyuczygTWM2OD1zLkS0{txO	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ3MEKyNUc,OjF4NUCyNlE9N2F-
HCT116	MkjpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				M1;0VGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzMEBKSzVyPUCuN\|HPxE1?	NH[1c3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NlQ6Pid-MkG3OFI1QTZ:L3G+
Sf9	MVXGeY5kfGmxbjDhd5NigQ>?		NGW5NJYzKGi{cx?=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiaX7jeYJifGWmIH\vdkAzKGi{czD1d4lv\yCUSFvLMWFkKG[udX;yc4dmdmmlIIP1ZpN1emG2ZTygTWM2OD1yLkGwNu69VQ>?	NV6wT2RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFkzODNpPkKzNFA6OjB\|PD;hQi=>
HCT116	M4jIWGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4XVdlczKGi{cx?=		MknHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4{OjgQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJyNki2O{c,OjN{ME[4Olc9N2F-
A549	NUTZXo9TS3m2b4TvfIlkcXS7IHHzd4F6		MX23NkBpenN?		MorDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUGuNlc6\|ryP	M1XWflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkC2PFY4Lz5{M{KwOlg3PzxxYU6=
MCF7	M2\mfmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGj3V\|A4OiCqcoO=		NWjs[ZRLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvQDB5zszN	M{L3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkC2PFY4Lz5{M{KwOlg3PzxxYU6=
HCT116	M3\1SWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWDlPY8yPzJiaILz		NHfNeYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZpkhdWWjc4XybY5oKGOnbHz1cIFzKEGWUDDs[ZZmdCCjZoTldkA4OiCqcoOgZpkh[2WubD30bZRmeiCpbH:gZZN{[XluIFnDOVA:OC55zszN	NXe1TGJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk1QDNpPkKzPFI6PDh\|PD;hQi=>
MCF7	MoT6R5l1d3SxeHnjbZR6KGG\|c3H5		M{HM[\|czKGi{cx?=		MkPPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDt[YF{fXKrbnegZ4VtdHWuYYKgRXRRKGyndnXsJIFnfGW{IEeyJIhzeyCkeTDj[YxtNXSrdHXyJIdtdyCjc4PhfUwhUUN3ME2xMlI3\|ryP	NHSzR5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVQ5Oyd-MkO4Nlk1QDN:L3G+
A549	M3TRXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3vWZVczKGi{cx?=		NWPldWNiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBu\WG\|dYLpcoch[2WubIXsZZIhSVSSIHzleoVtKGGodHXyJFczKGi{czDifUBk\WyuLYTpeIVzKGeubzDhd5NigSxiSVO1NF0yNjd\|zszN	Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
DU145	Mn31R5l1d3SxeHnjbZR6KGG\|c3H5		MkTrO\|IhcHK\|		NF3me\|FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBu\WG\|dYLpcoch[2WubIXsZZIhSVSSIHzleoVtKGGodHXyJFczKGi{czDifUBk\WyuLYTpeIVzKGeubzDhd5NigSxiSVO1NF0zNjB4zszN	Mn;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
Jurkat	M4\tNWFxd3C2b4Ppd{Bie3OjeR?=	M2H4OFEhfG9iMUCgeW0>	NVG5b2p5OjRiaILz		MnjVTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M1rHSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
HeLa	MXrGeY5kfGmxbjDhd5NigQ>?	MlfMNUB1dyBzMDD1US=>	NFXTbGwzPCCqcoO=		NHe5U5BKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBJO0t7QXOgcIV3\WxiYYSgNUB1dyBzMDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MoXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
Jurkat	M1HVUGZ2dmO2aX;uJIF{e2G7	M3PTflEhfG9iMUCgeW0>	MnLJNlQhcHK\|		MYXJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGg{UzmDYzDs[ZZmdCCjdDCxJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MlvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
High5	MXrGeY5kfGmxbjDhd5NigQ>?		NX21VZdtOyC2bzCyOEBpenN?		NX;lbmpSUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JIhq\2h3IHPlcIx{KHW\|aX7nJGFkNUy7cz3UfZIuVHm\|IDjldJNqdG:wLXHj[ZR6dClvQV3DJIF{KHO3YoP0doF1\SCjZoTldkA{KHSxIEK0JIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;MD65Oe69VQ>?	NH;LcWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVAyQCd-MkSwPVUxOTh:L3G+
HCT116	NEnrXoxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHTUdXk4OiCqcoO=		NX;ZbmNNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlU4\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUCxPEc,OjRyOUWwNVg9N2F-
A549	NGjiS\|BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4f3R\|czKGi{cx?=		M3KwPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFwNkZOwG0>	NYXIbGxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOThpPkK0NFk2ODF6PD;hQi=>
High5	M33MdmZ2dmO2aX;uJIF{e2G7		NUXacJpmOyC2bzCyOEBpenN?		M4XWfmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDobYdpPSClZXzsd{B2e2mwZzDBZ{1NgXNvVInyMWx6eyBqZYDzbYxwdi2jY3X0fYwqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgN{B1dyB{NDDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTFwNkhOwG0>	NGrLUJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVAyQCd-MkSwPVUxOTh:L3G+
SNU16	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MWS3NkBpenN?		NWr4XJV7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW06XMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkG0Nu69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
High5	MV\GeY5kfGmxbjDhd5NigQ>?		M{OxV\|I1KGi{cx?=		NFr6UnJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFjERWMzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgTIlocDViY3XscJMhfXOrbnegRYMuVHm\|LWT5dk1NgXNiKHXwd4ltd25vYXPleJltMS2DTVOgZZMhe3Wkc4TyZZRmKGGodHXyJFI1KGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4yP87:TR?=	NX\JV29RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
High5	Mki2SpVv[3Srb36gZZN{[Xl?		Mki0N{BpenN?		NW\KUY4yUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDISGFEOyCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JGhq\2h3IHPlcIx{KHW\|aX7nJGFkNUy7cz3UfZIuVHm\|IDjldJNqdG:wLXHj[ZR6dClvQV3DJIF{KHO3YoP0doF1\SCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4{Ps7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
High5	NWnpTIp6TnWwY4Tpc44h[XO\|YYm=		NYmyTJB3OjRiaILz		NUPzNnRRUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JGhq\2h3IHPlcIx{KHW\|aX7nJGFkNUy7cz3UfZIuVHm\|IDjldJNqdG:wLXHj[ZR6dClvQV3DJIF{KHO3YoP0doF1\SCjZoTldkAzPCCqcoOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwQVAvOzoQvF2=	NWf1V3BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
HCT116	Mn7KR5l1d3SxeHnjbZR6KGG\|c3H5		Mo\FO\|IhcHK\|		M3vrb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwM{m2{txO	MknVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
SW620	MoL3R5l1d3SxeHnjbZR6KGG\|c3H5		MkO4O\|IhcHK\|		NH;UVohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwNEG5{txO	MkTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
MKN45	NY\tTVJNS3m2b4TvfIlkcXS7IHHzd4F6		MkL1O\|IhcHK\|		M4jnbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjR3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC54Md88US=>	NY\lNmRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
Hep3B	NX60RopOS3m2b4TvfIlkcXS7IHHzd4F6		MUi3NkBpenN?		NFjSXoFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XB\|QjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwOEKz{txO	Ml\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
HepG2	NY[2eI1uS3m2b4TvfIlkcXS7IHHzd4F6		NU\j[HZCPzJiaILz		M{DPTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC56N{dOwG0>	NW\PdGtFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
SNU5	MnvJR5l1d3SxeHnjbZR6KGG\|c3H5		M1jmNlczKGi{cx?=		M37aW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTViY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjByOd88US=>	NVjJdWVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
A549	M4LzSmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoDJO\|IhcHK\|		MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9Nk4xQM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
SJSA1	NVPKXoR5S3m2b4TvfIlkcXS7IHHzd4F6		MUK3NkBpenN?		MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTnNCOSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvPjJ2zszN	M4HROlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC1OFQ3Lz5{NUiwOVQ1PjxxYU6=
MHCC97H	NE\OO2xEgXSxdH;4bYNqfHliYYPzZZk>		NWHjW3VwPzJiaILz		M{XWbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1JS0N7N1igZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12LkW2N:69VQ>?	NYnxV2wxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
PANC1	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		NGOxWIU4OiCqcoO=		NXPKflRKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEGQQ{GgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Nj63O\|TPxE1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
U937	MoLzSpVv[3Srb36gZZN{[Xl?	M2XlU\|ExKHWP	MlWxNlQhcHK\|		NFzsZ5BKdmirYnn0bY9vKG:oIFjERWM{KGmwIHj1cYFvKFV7M{egZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUuQSCjY3X0fYxifGmxbjDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6N{OxNEc,OjZ{OEezNVA9N2F-
PC3	Mo\DSpVv[3Srb36gZZN{[Xl?	NVPSSXFwOTBidV2=	MXmyOEBpenN?		NH3NPJZKdmirYnn0bY9vKG:oIFjERWM{KGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[U06KGGlZYT5cIF1cW:wIHH0JFExKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k	M1W3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki3N\|ExLz5{NkK4O\|MyODxxYU6=
U937	NEHnSXNHfW6ldHnvckBie3OjeR?=	NIPRVFIyOCC3TR?=	M{XzflI1KGi{cx?=		MV7Jcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gWVk{PyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ5lkdGmwIFWg[ZhxemW\|c3nvckBqdiCjdDCxNEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJI1mfGixZB?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6N{OxNEc,OjZ{OEezNVA9N2F-
Sf9	Mn\nSpVv[3Srb36gZZN{[Xl?		M2S3VlExKG2rboO=		MnTLTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDDMZRmem2rbnHsJGZNSUdvdHHn[4VlKEiGQVOxNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGOnbHzzJJV{cW6pIFLvZ{1NgXNqZYDzbYxwdi2DYzmtRW1EKGG\|IIP1ZpN1emG2ZTDwdoV1emWjdHXkJIZweiBzMDDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDifUBndHWxcn;t[ZRzcWNibXX0bI9lNCCLQ{WwQVAvPToQvF2=	NVXsOWVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
TC32	NX3yWnlveUiWUzDhd5NigQ>?				MoXodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	MkLTdWhVWyCjc4PhfS=>				NYfWUHVseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	MoS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NYO5e2ZkeUiWUzDhd5NigQ>?				NUDkeVBieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	NFPtTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MofCdWhVWyCjc4PhfS=>				NGfVS3dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NVS0ZZZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NVrIdJh1eUiWUzDhd5NigQ>?				NFLxNGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M1nzdJFJXFNiYYPzZZk>				NIPnPFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	NX;NeFJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MnP1dWhVWyCjc4PhfS=>				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	M1W4epFJXFNiYYPzZZk>				NHzvXY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MX\xTHRUKGG\|c3H5				M2\4dJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NV25SI9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NF\WN4VyUFSVIHHzd4F6				M3SxbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NXGxTXNKeUiWUzDhd5NigQ>?				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MofDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NHXZeVZyUFSVIHHzd4F6				NXzpZYFreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M4fWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M2DU[pFJXFNiYYPzZZk>				M3rjXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MUDxTHRUKGG\|c3H5				NULoN4t5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NVnHUpkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M2TJSpFJXFNiYYPzZZk>				NFvHTZRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NFi4bpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NVvWRWlWeUiWUzDhd5NigQ>?				MlO3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MnP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MWDxTHRUKGG\|c3H5				M2LtdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
fibroblast cells	M2fKepFJXFNiYYPzZZk>				MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	NU[4NWxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MX3xTHRUKGG\|c3H5				MlfsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M2fnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MlPydWhVWyCjc4PhfS=>				Mn\adWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M2PjfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NFnVdG9yUFSVIHHzd4F6				MoC1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsdy=>	NHX5NlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NXTZb4lleUiWUzDhd5NigQ>?				NX7yb21teUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MkHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NVXPeoNpeUiWUzDhd5NigQ>?				NEO3U2tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M{Dqd5FJXFNiYYPzZZk>				MnzQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	NX:zR3N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NIDDXIhyUFSVIHHzd4F6				NX;kZZI5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MYnxTHRUKGG\|c3H5				MmS3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	M1nxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Sf9	NH[zTJNHfW6ldHnvckBie3OjeR?=				MXfJcohq[mm2aX;uJGF{e2G7OjDISGFEKGmwaHnibZRqd25iYYPzZZl{KHencnWgdIVz\m:{bXXkJIJ6KFKnYXP0bY9vKEKrb3zv[5khS2:{cD6gLG1idH[ncn6sJHBiNilidYPpcochcXOxbHH0[YQhcHWvYX6sJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIFjERWMyKGGwZDCtOkBnem:vIHGgZoFkfWyxdnnyeZMh\XiycnXzd4lwdiC\|eYP0[Y0hcW5iU3[5JINmdGy\|LDDJR\|UxRTBwMUCy{txO	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HCT116	NV:5emFuSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4W5V\|Q5KGi{cx?=		NV;OXnBbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5{NN88US=>	NVu4NmNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
MCF7	M{f1NWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn3YO\|IhcHK\|		NYDnVW5NSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvPDoQvF2=	NHXOco49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HeLa	NH2zWYhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXmxeVBOPDhiaILz		M4PhdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlMz\|ryP	NWXj[WJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
HeLa	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3PYelczKGi{cx?=		NYX5SmVPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvPDMQvF2=	M{Tv[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HCT116	MlvqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2LuZlczKGi{cx?=		MojwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N{42Oc7:TR?=	NYPuVGNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
HepG2	NGX0boJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoraOFghcHK\|		MoCzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlA2\|ryP	M1zSZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HepG2	NF;yblRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVnSXGd7PzJiaILz		NYW1eJdPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01NjJ3zszN	M3;nR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HepG2	M1nPfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NITsXmozPCCqcoO=		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUWuO\|nPxE1?	NVXmfWdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
A549	M2nyO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoXNO\|IhcHK\|		M17TOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNU45P87:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
A549	NUfZNZlwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUPGU4VkPDhiaILz		MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MUSuOVfPxE1?	NGO0b3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HCT116	MkXZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoPkNlQhcHK\|		NHXrRpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zQS54Od88US=>	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HeLa	NXfORpduSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXSyOEBpenN?		NX7We4RpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQ{NjkQvF2=	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-H3 / Ac-H4 / Ac-tubulin ; PubMed: 29186204 PLoS One Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression. Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; PubMed: 27551526 Cell Death Discov (a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies.	29186204 27551526
Immunofluorescence	Nanog / MHC ; PubMed: 26240433 Stem Cells Transl Med c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm. E-cadherin / ZEB1 ; PubMed: 25872941 EMBO Mol Med Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.	26240433 25872941
Growth inhibition assay	Cell viability; PubMed: 26378038 Oncotarget B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software.	26378038

In vivo

MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. ^[1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse HDAC enzyme assay in vitro: The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:^[1]	- Collapse Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells Concentrations: 0-60 μM Incubation Time: 72 hours Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO₂. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5 (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female CD-1 nude mice bearing H1437 tumors Dosages: 80 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL (32.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% Propylene glycol For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Mocetinostat (MGCD0103) SDF

Molecular Weight	396.44
Formula	C₂₃H₂₀N₆O
CAS No.	726169-73-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MG0103
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04299113	Recruiting	Drug: Vinorelbine\|Drug: Mocetinostat	Rhabdomyosarcoma	Jonsson Comprehensive Cancer Center\|Mirati Therapeutics Inc.\|Phase One Foundation	May 14 2020	Phase 1
NCT02993991	Withdrawn	Drug: Mocetinostat\|Biological: Durvalumab	Squamous Cell Carcinoma Head And Neck\|Squamous Cell Carcinoma Mouth\|Resectable Squamous Cell Carcinoma of Oral Cavity	University Health Network Toronto\|Mirati Therapeutics Inc.\|AstraZeneca	October 10 2017	Phase 1
NCT02805660	Completed	Drug: mocetinostat\|Drug: durvalumab	Advanced Cancer	Mirati Therapeutics Inc.	May 2016	Phase 1\|Phase 2
NCT02236195	Completed	Drug: Mocetinostat	Urothelial Carcinoma	Mirati Therapeutics Inc.	October 2014	Phase 2
NCT00666497	Terminated	Drug: Azacitidine\|Drug: MGCD0103	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	Mirati Therapeutics Inc.	June 2008	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitors

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitors

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Mocetinostat (MGCD0103)